.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Julphar
Moodys
Deloitte
Express Scripts
Teva
Colorcon
Chinese Patent Office
Cipla
Fuji

Generated: December 16, 2017

DrugPatentWatch Database Preview

Alimera Sciences Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ALIMERA SCIENCES INC, and when can generic versions of ALIMERA SCIENCES INC drugs launch?

ALIMERA SCIENCES INC has one approved drug.

There are five US patents protecting ALIMERA SCIENCES INC drugs.

There are one hundred and sixty-five patent family members on ALIMERA SCIENCES INC drugs in twenty-six countries and one supplementary protection certificate in one country.

Summary for Alimera Sciences Inc

International Patents:165
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Alimera Sciences IncILUVIENfluocinolone acetonideIMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Alimera Sciences Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,439,249Inhibitors of phosphatases► Subscribe
9,566,336In situ gelling drug delivery system► Subscribe
8,815,284Bioerodible sustained release drug delivery systems► Subscribe
9,192,579Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,659Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,613Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Alimera Sciences Inc Drugs

Country Document Number Estimated Expiration
Spain2340389► Subscribe
South Korea20050007377► Subscribe
Taiwan200505507► Subscribe
Japan2002539263► Subscribe
European Patent Office1276462► Subscribe
South Korea20010112357► Subscribe
European Patent Office1162978► Subscribe
Canada2484632► Subscribe
World Intellectual Property Organization (WIPO)0180825► Subscribe
MexicoPA01009544► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Alimera Sciences Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000063Germany► SubscribePRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Harvard Business School
McKesson
US Army
Citi
Medtronic
Healthtrust
Novartis
US Department of Justice
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot